截至XNUMX月底的一周,生物技術股上漲。 疫苗新聞流引發的反彈也推高了大盤,這是13日。本週始于輝瑞公司的積極消息。 (NYSE:PFE)及其德國合作夥伴BioNTech SE – ADR(NASDAQ:BNTX)報告了他們共同研發的針對COVID-3冠狀病毒的mRNA疫苗的中期19期陽性數據。競爭對手疫苗開發商Moderna Inc(NASDAQ: MRNA)在達到其首次中期分析的法定病例數時也產生了樂觀.300 Prime Therapeutics Inc(NASDAQ:FPRX)在一周內上漲了XNUMX%以上,其上漲主要是由於其研究階段中期的積極研究與此同時,Supernus Pharmaceuticals Inc(納斯達克股票代碼:SUPN)在FDA拒絕其ADHD藥物後受到壓力,收益消息繼續流傳,但本週在IPO方面保持沉默。 在本週內舉行了多次會議,這使生物製藥公司有機會展示他們正在研究的產品的新數據。以下是XNUMX月開始的一周的主要推動因素。 13,會議*美國眼科學會(AAO),2020年虛擬會議:XNUMX月。 13-15日*美國肝臟疾病研究協會(AASLD),肝臟會議,數字體驗:XNUMX月。 13-16日*古根海姆醫療保健講座,創意論壇,第二屆年度神經/免疫學日:2月。 16 * Stifel 2020虛擬醫療會議:XNUMX月。 16-18日* Jefferies虛擬倫敦醫療保健會議:XNUMX月。 17-19日* Wolfe研究虛擬醫療會議:XNUMX月。 18-19 *結締組織腫瘤學會或CTOS,虛擬年度會議:XNUMX月。 18-21 * SVB Leerink腫瘤學日:XNUMX月。 19 * 2020神經腫瘤學會或SNO,虛擬會議:XNUMX月。 19-21PDUFA日期FDA決定對精神分裂症和雙相性I型疾病的ALKS 3831進行Alkermes Plc(NASDAQ:ALKS)NDA裁決。 (星期天)週日,阿達米斯藥業公司(納斯達克股票代碼:ADMP)Zimhi(阿片類藥物過量的研究治療藥物)的命運也將由FDA決定。富馬酸二甲酯,由Biogen Inc(NASDAQ:BIIB)生產的一種通用版本,用於治療復發性多發性硬化症。 FDA將PDUFA的日期定為XNUMX月。 Bristol-Myers Squibb Co's(NYSE:BMY)BLA for Liso-cel為16,是至少經過兩次以上治療後復發或難治性大B細胞淋巴瘤患者的治療選擇。 (星期一)艾格生物製藥公司(納斯達克股票代碼:EIGR)在XNUMX月與FDA等待決定性的時刻。 關於Lonfarnib在早衰和早衰型laminopathy方面的NDA評估為20。 臨床讀出/數據演示AAO會議演示譜系細胞治療公司(紐約證券交易所代碼:LCTX):正在進行的1 / 2a階段主要研究結果更新了其領先的候選藥物OpRegen在與乾齡相關的黃斑變性中的研究。 (Sunday); the company has also scheduled a call with key opinion leaders Tuesday, 4 pm ET, to discuss the data.AASLD Presentations Albireo Pharma Inc (NASDAQ: ALBO): new data from a Phase 3 study of odevixibat in progressive familial intrahepatic cholestasis (Sunday)Inventiva ADR Representing Ord Shs (NASDAQ: IVA): new data from the NATIVE Phase 2b clinical trial evaluating lanifibranor for NASH, focusing on the efficacy of lanifibranor in type-2 diabetic patients and its positive effect on key plasma biomarkers (Sunday)Akero Therapeutics Inc (NASDAQ: AKRO): additional data analysis from the Phase 2a BALANCED study of efruxifermin in non-alcoholic steatohepatitis (Sunday)Dicerna Pharmaceuticals Inc (NASDAQ: DRNA): Updated Phase 1 data for RG6346 in HBV infection (Monday)CymaBay Therapeutics Inc (NASDAQ: CBAY): a late-breaking presentation highlighting results from the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis (Monday)Related Link: 7 Stocks That Could Benefit From Pfizer’s COVID-19 Vaccine That Requires Cold Chain Storage SNO Meeting Presentations VBI Vaccines Inc (NASDAQ: VBIV): data from Part B of the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (Thursday)Kintara Therapeutics Inc (NASDAQ: KTRA): update on Phase 2 studies of VAL-083 in MGMT-unmethylated Recurrent Glioblastoma Multiforme (Thursday)Plus Therapeutics Inc (NASDAQ: PSTV): new interim data from the ongoing NIH-sponsored ReSPECT Phase 1 clinical trial evaluating its lead investigational asset, Rhenium NanoLiposome in patients with recurrent glioblastoma (Thursday)CTOS Presentations Karyopharm Therapeutics Inc (NASDAQ: KPTI): data from the Phase 3 portion of the SEAL study of Xpovio in advanced dedifferentiated liposarcomaCogent Biosciences Inc (NASDAQ: COGT): final clinical data from its Phase 1/2 study of PLX9486 in gastrointestinal stromal tumorsStandalone Data Readouts Avrobio Inc (NASDAQ: AVRO) will announce at its Virtual R&D Day scheduled for Tuesday additional details on its new Hunter syndrome program, while also sharing new data on its three clinical programs, including initial clinical data from its Gaucher disease program.Pfizer and BioNTech expect safety data milestone to be achieved in the third week of November and plan for emergency use authorization shortly after.Moderna could release interim Phase 3 readout for its coronavirus vaccine candidate, given it has said it has reached the mandated number of cases for analysis.Earnings Monday Vascular Biogenics Ltd (NASDAQ: VBLT) (before the market open) Jaguar Health Inc (NASDAQ: JAGX) (before the market open) Celsion Corporation (NASDAQ: CLSN) (before the market open)Tuesday Trinity Biotech plc (NASDAQ: TRIB) (before the market open) PAVmed Inc (NASDAQ: PAVM)Wednesday Edap Tms SA (NASDAQ: EDAP) (after the close)Thursday Precipio Inc (NASDAQ: PRPO) (after the close)Friday Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open)IPOs San Diego, California-based Maravai Lifsciences Holding, Inc. 該公司計劃在首次公開發行中以50至24美元的價格出售其27萬股普通股。 該公司提供的關鍵產品可以實現藥物療法,診斷學,新型疫苗的開發以及對人類疾病的支持研究,該公司表示其股票將在納斯達克上市,股票代碼為MRVI.Sotera Health Company是一家滅菌實驗室。測試和諮詢服務公司已向SEC提交了招股說明書,以發行其46.6萬股普通股,發行價格在20美元至23美元之間。 這家總部位於俄亥俄州Broadview Heights的公司已申請將其股票在納斯達克上市,股票代碼為SHC。IPO安靜期到期Foghorn Therapeutics Inc. (納斯達克股票代碼:FHTX)查看本辛加的更多信息*單擊此處以查看本辛加的期權交易* Moderna首次讀取臨時報告的COVID-19案號:下一步是什麼? *輝瑞冠狀病毒疫苗數據對Moderna(C)2020 Benzinga.com的意義。 Benzinga不提供投資建議。
截至XNUMX月底的一周,生物技術股上漲。 疫苗新聞流引發的反彈也推高了大盤,這是13日。本週始于輝瑞公司的積極消息。 (NYSE:PFE)及其德國合作夥伴BioNTech SE – ADR(NASDAQ:BNTX)報告了他們共同研發的針對COVID-3冠狀病毒的mRNA疫苗的中期19期陽性數據。競爭對手疫苗開發商Moderna Inc(NASDAQ: MRNA)在達到其首次中期分析的法定病例數時也產生了樂觀.300 Prime Therapeutics Inc(NASDAQ:FPRX)在一周內上漲了XNUMX%以上,其上漲主要是由於其研究階段中期的積極研究與此同時,Supernus Pharmaceuticals Inc(納斯達克股票代碼:SUPN)在FDA拒絕其ADHD藥物後受到壓力,收益消息繼續流傳,但本週在IPO方面保持沉默。 在本週內舉行了多次會議,這使生物製藥公司有機會展示他們正在研究的產品的新數據。以下是XNUMX月開始的一周的主要推動因素。 13,會議*美國眼科學會(AAO),2020年虛擬會議:XNUMX月。 13-15日*美國肝臟疾病研究協會(AASLD),肝臟會議,數字體驗:XNUMX月。 13-16日*古根海姆醫療保健講座,創意論壇,第二屆年度神經/免疫學日:2月。 16 * Stifel 2020虛擬醫療會議:XNUMX月。 16-18日* Jefferies虛擬倫敦醫療保健會議:XNUMX月。 17-19日* Wolfe研究虛擬醫療會議:XNUMX月。 18-19 *結締組織腫瘤學會或CTOS,虛擬年度會議:XNUMX月。 18-21 * SVB Leerink腫瘤學日:XNUMX月。 19 * 2020神經腫瘤學會或SNO,虛擬會議:XNUMX月。 19-21PDUFA日期FDA決定對精神分裂症和雙相性I型疾病的ALKS 3831進行Alkermes Plc(NASDAQ:ALKS)NDA裁決。 (星期天)週日,阿達米斯藥業公司(納斯達克股票代碼:ADMP)Zimhi(阿片類藥物過量的研究治療藥物)的命運也將由FDA決定。富馬酸二甲酯,由Biogen Inc(NASDAQ:BIIB)生產的一種通用版本,用於治療復發性多發性硬化症。 FDA將PDUFA的日期定為XNUMX月。 Bristol-Myers Squibb Co's(NYSE:BMY)BLA for Liso-cel為16,是至少經過兩次以上治療後復發或難治性大B細胞淋巴瘤患者的治療選擇。 (星期一)艾格生物製藥公司(納斯達克股票代碼:EIGR)在XNUMX月與FDA等待決定性的時刻。 關於Lonfarnib在早衰和早衰型laminopathy方面的NDA評估為20。 臨床讀出/數據演示AAO會議演示譜系細胞治療公司(紐約證券交易所代碼:LCTX):正在進行的1 / 2a階段主要研究結果更新了其領先的候選藥物OpRegen在與乾齡相關的黃斑變性中的研究。 (Sunday); the company has also scheduled a call with key opinion leaders Tuesday, 4 pm ET, to discuss the data.AASLD Presentations Albireo Pharma Inc (NASDAQ: ALBO): new data from a Phase 3 study of odevixibat in progressive familial intrahepatic cholestasis (Sunday)Inventiva ADR Representing Ord Shs (NASDAQ: IVA): new data from the NATIVE Phase 2b clinical trial evaluating lanifibranor for NASH, focusing on the efficacy of lanifibranor in type-2 diabetic patients and its positive effect on key plasma biomarkers (Sunday)Akero Therapeutics Inc (NASDAQ: AKRO): additional data analysis from the Phase 2a BALANCED study of efruxifermin in non-alcoholic steatohepatitis (Sunday)Dicerna Pharmaceuticals Inc (NASDAQ: DRNA): Updated Phase 1 data for RG6346 in HBV infection (Monday)CymaBay Therapeutics Inc (NASDAQ: CBAY): a late-breaking presentation highlighting results from the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis (Monday)Related Link: 7 Stocks That Could Benefit From Pfizer’s COVID-19 Vaccine That Requires Cold Chain Storage SNO Meeting Presentations VBI Vaccines Inc (NASDAQ: VBIV): data from Part B of the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (Thursday)Kintara Therapeutics Inc (NASDAQ: KTRA): update on Phase 2 studies of VAL-083 in MGMT-unmethylated Recurrent Glioblastoma Multiforme (Thursday)Plus Therapeutics Inc (NASDAQ: PSTV): new interim data from the ongoing NIH-sponsored ReSPECT Phase 1 clinical trial evaluating its lead investigational asset, Rhenium NanoLiposome in patients with recurrent glioblastoma (Thursday)CTOS Presentations Karyopharm Therapeutics Inc (NASDAQ: KPTI): data from the Phase 3 portion of the SEAL study of Xpovio in advanced dedifferentiated liposarcomaCogent Biosciences Inc (NASDAQ: COGT): final clinical data from its Phase 1/2 study of PLX9486 in gastrointestinal stromal tumorsStandalone Data Readouts Avrobio Inc (NASDAQ: AVRO) will announce at its Virtual R&D Day scheduled for Tuesday additional details on its new Hunter syndrome program, while also sharing new data on its three clinical programs, including initial clinical data from its Gaucher disease program.Pfizer and BioNTech expect safety data milestone to be achieved in the third week of November and plan for emergency use authorization shortly after.Moderna could release interim Phase 3 readout for its coronavirus vaccine candidate, given it has said it has reached the mandated number of cases for analysis.Earnings Monday Vascular Biogenics Ltd (NASDAQ: VBLT) (before the market open) Jaguar Health Inc (NASDAQ: JAGX) (before the market open) Celsion Corporation (NASDAQ: CLSN) (before the market open)Tuesday Trinity Biotech plc (NASDAQ: TRIB) (before the market open) PAVmed Inc (NASDAQ: PAVM)Wednesday Edap Tms SA (NASDAQ: EDAP) (after the close)Thursday Precipio Inc (NASDAQ: PRPO) (after the close)Friday Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open)IPOs San Diego, California-based Maravai Lifsciences Holding, Inc. 該公司計劃在首次公開發行中以50至24美元的價格出售其27萬股普通股。 該公司提供的關鍵產品可以實現藥物療法,診斷學,新型疫苗的開發以及對人類疾病的支持研究,該公司表示其股票將在納斯達克上市,股票代碼為MRVI.Sotera Health Company是一家滅菌實驗室。測試和諮詢服務公司已向SEC提交了招股說明書,以發行其46.6萬股普通股,發行價格在20美元至23美元之間。 這家總部位於俄亥俄州Broadview Heights的公司已申請將其股票在納斯達克上市,股票代碼為SHC。IPO安靜期到期Foghorn Therapeutics Inc. (納斯達克股票代碼:FHTX)查看本辛加的更多信息*單擊此處以查看本辛加的期權交易* Moderna首次讀取臨時報告的COVID-19案號:下一步是什麼? *輝瑞冠狀病毒疫苗數據對Moderna(C)2020 Benzinga.com的意義。 Benzinga不提供投資建議。
,